EUVIMEDEUVIMED entdecken
Leitlinie

2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

Lisa R Sammaritano, Anca Askanase iD, Bonnie L Bermas iD, Maria Dall'Era, Alí Duarte-García iD, Linda T Hiraki iD, Brad H Rovin iD, Mary Beth F Son, Anthony Alvarado, Cynthia Aranow iD, April Barnado iD, Anna Broder und 40 weitere

Arthritis & Rheumatology · 2025-09 · 77 (9) · 1115-1135

DOI: 10.1002/art.43212 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 07.05.2025. Verfasst von Lisa R Sammaritano und 51 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery - Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Lupus Nephritis, Immunosuppressive Agents, Glucocorticoids. Die Arbeit wurde bisher 157-mal zitiert (Crossref) und nennt 127 Literaturangaben. Gefördert von: NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.

Methods

The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.

Results

We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.

Conclusion

This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisImmunosuppressive AgentsGlucocorticoidsHumansRheumatologySocieties, MedicalMass Screening

Substanzen

Immunosuppressive AgentsGlucocorticoids

Autor:innen und Institutionen

  • Hospital for Special Surgery - Weill Cornell Medicine, New York, New York.
  • Columbia University, New York, New York.
  • UT Southwestern Medical Center, Dallas, Texas.
  • University of California, San Francisco.
  • Mayo Clinic, Rochester, Minnesota.
  • The Hospital for Sick Children, Toronto, Ontario, Canada.

ORCID-Profile: Anca Askanase, Bonnie L Bermas, Alí Duarte-García, Linda T Hiraki, Brad H Rovin, Cynthia Aranow, April Barnado, Hermine I Brunner, Elizabeth D Ferucci, Aimee O Hersh, Benjamin J Smith, Daniel J Wallace, Christie M Bartels, Kimberly DeQuattro, Gabriel Figueroa-Parra, Shivani Garg, April Jorge, Shanthini Kasturi, Hassan Kawtharany, Kyriakos A Kirou, Megan M Lockwood, Alain Sanchez-Rodriguez, Jessica N Williams, Amy S Turner

Förderung

  • NIAMS NIH HHS

Zitieren

APA

Sammaritano, L. R., Askanase, A., Bermas, B. L., Dall'Era, M., Duarte-García, A., Hiraki, L. T., Rovin, B. H., Son, M. B. F., Alvarado, A., Aranow, C., Barnado, A., Broder, A., Brunner, H. I., Chowdhary, V., Contreras, G., Felix, C., Ferucci, E. D., Gibson, K. L., Hersh, A. O., …, & Mustafa, R. A. (2025). 2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis & Rheumatology, 77(9), 1115-1135. https://doi.org/10.1002/art.43212

Vancouver

Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Hiraki LT, et al. 2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis & Rheumatology. 2025;77(9):1115-1135. doi:10.1002/art.43212

BibTeX
@article{Sammaritano2025,
  author = {Sammaritano, Lisa R and Askanase, Anca and Bermas, Bonnie L and Dall'Era, Maria and Duarte-García, Alí and Hiraki, Linda T and Rovin, Brad H and Son, Mary Beth F and Alvarado, Anthony and Aranow, Cynthia and Barnado, April and Broder, Anna and Brunner, Hermine I and Chowdhary, Vaidehi and Contreras, Gabriel and Felix, Christele and Ferucci, Elizabeth D and Gibson, Keisha L and Hersh, Aimee O and Izmirly, Peter M and Kalunian, Kenneth and Kamen, Diane and Rollins, Brandi and Smith, Benjamin J and Thomas, Asha and Timlin, Homa and Wallace, Daniel J and Ward, Michael and Azzam, Muayad and Bartels, Christie M and Cunha, Joanne S and DeQuattro, Kimberly and Fava, Andrea and Figueroa-Parra, Gabriel and Garg, Shivani and Greco, Jessica and Cuéllar-Gutiérrez, Maria C and Iyer, Priyanka and Johannemann, Andrew S and Jorge, April and Kasturi, Shanthini and Kawtharany, Hassan and Khawandi, Jana and Kirou, Kyriakos A and Legge, Alexandra and Liang, Kelly V and Lockwood, Megan M and Sanchez-Rodriguez, Alain and Turgunbaev, Marat and Williams, Jessica N and Turner, Amy S and Mustafa, Reem A},
  title = {2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {9},
  pages = {1115--1135},
  doi = {10.1002/art.43212}
}
Kostenlos starten →